Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets

Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets.
Strativa Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the remedying of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children life-span 16 and older pills for party. Oravig is the fundamental and only local, spoken remedy formulation of miconazole - an antifungal medication - approved for this use in the US.

Oravig, which adheres to the gum, utilizes innovative buccal bolus technology enabling once-daily dosing that delivers miconazole speedily at the local site of infection throughout the day with minimal systemic absorption penis enhancement. Oravig is easy-to-use and provides patients with a flavorless, odorless and serviceable treatment option that does not interfere with continually activities such as eating and drinking.

Oravig will be offered in a 50 mg dosage strength and is expected to be handy in retail pharmacies in the third quarter of 2010. "The FDA approval of Oravig underscores Strativa's commitment to improving patients' overall care experience by bringing to market new products that fulfill long-suffering needs," said John A MacPhee, President, Strativa Pharmaceuticals. "Oravig offers patients agony from thrush a proven effective treatment in a discreet and available once-daily formulation".

The FDA approval was based on two pivotal Phase III clinical trials. The win study demonstrated that Oravig completely resolved signs and symptoms of OPC at rates equivalent to Mycelex Troche (clotrimazole) administered five times per daytime in HIV-positive patients. This randomized, double-blind, double-dummy trial was conducted in 577 HIV-positive patients in 28 sites in the United States, Canada, and South Africa. A shift randomized, open-label, multicenter comparative hard luck conducted in 282 patients who underwent radiotherapy for leadership and neck cancer showed that Oravig is safe and effective in this patient population who often has reduced salivary flow.